by GlobeNewsWire | Jan 7, 2018 | Globe Newswire
NOVATO, Cali., Jan. 07, 2018 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim safety and efficacy data...